(XRAY) Dentsply Sirona - Overview
Stock: Imaging Equipment, Dental Handpieces, Aligners, Implants, Catheters
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.74% |
| Yield on Cost 5y | 1.28% |
| Yield CAGR 5y | 10.45% |
| Payout Consistency | 95.7% |
| Payout Ratio | 91.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 43.3% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.51 |
| Alpha | -42.34 |
| Character TTM | |
|---|---|
| Beta | 1.131 |
| Beta Downside | 0.852 |
| Drawdowns 3y | |
|---|---|
| Max DD | 74.96% |
| CAGR/Max DD | -0.34 |
Description: XRAY Dentsply Sirona January 12, 2026
DENTSPLY SIRONA Inc. (NASDAQ: XRAY) designs, manufactures, and sells a broad portfolio of dental and urology/enterology products, ranging from cloud-enabled imaging and intra-oral scanners to orthodontic aligners and intermittent urinary catheters. The firm operates through four reporting segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic & Implant Solutions, and Wellspect Healthcare.
The Connected Technology Solutions segment bundles digital imaging, motorized handpieces, CEREC chair-side ceramic restorations, 3-D printers and intra-oral scanners-tools that enable fully digital treatment workflows. Essential Dental Solutions supplies the consumables and instruments needed for root-canal therapy, restorative dentistry, and prophylaxis. Orthodontic & Implant Solutions covers the SureSmile clear-aligner platform, implant hardware, digital dentures, and related software, while Wellspect Healthcare focuses on urinary catheters (LoFric) and irrigation systems (Navina).
Key industry dynamics that drive Dentsply Sirona’s outlook include: (1) the aging U.S. and global population, which is expanding the addressable market for restorative and implant procedures; (2) accelerating adoption of digital dentistry-estimated to grow at a 9-10% CAGR through 2028-fueling demand for scanners, CAD/CAM systems, and chair-side solutions; and (3) reimbursement pressure on traditional consumables, pushing providers toward higher-margin, technology-enabled services.
Recent performance metrics (as of FY 2024) show revenue of roughly $5.1 billion, a year-over-year growth rate of 3.2%, and an operating margin of 12.5%, reflecting the higher profitability of the Connected Technology Solutions segment relative to the lower-margin consumables business. R&D spending remains around 7% of revenue, underscoring the company’s commitment to maintaining its digital-technology lead.
If you want a data-driven deep dive, checking ValueRay’s analyst dashboard for XRAY can provide the quantitative context needed to evaluate these trends.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -882.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -4.09 > 1.0 |
| NWC/Revenue: 18.41% < 20% (prev 9.72%; Δ 8.69% < -1%) |
| CFO/TA 0.04 > 3% & CFO 221.0m > Net Income -882.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (199.5m) vs 12m ago -0.75% < -2% |
| Gross Margin: 50.86% > 18% (prev 0.52%; Δ 5033 % > 0.5%) |
| Asset Turnover: 59.03% > 50% (prev 58.86%; Δ 0.17% > 0%) |
| Interest Coverage Ratio: -9.87 > 6 (EBITDA TTM -432.0m / Interest Expense TTM 79.0m) |
Altman Z'' -1.40
| A: 0.12 (Total Current Assets 2.07b - Total Current Liabilities 1.41b) / Total Assets 5.65b |
| B: -0.25 (Retained Earnings -1.39b / Total Assets 5.65b) |
| C: -0.13 (EBIT TTM -780.0m / Avg Total Assets 6.14b) |
| D: -0.49 (Book Value of Equity -2.05b / Total Liabilities 4.17b) |
| Altman-Z'' Score: -1.40 = CCC |
Beneish M -3.32
| DSRI: 1.05 (Receivables 654.0m/671.0m, Revenue 3.62b/3.90b) |
| GMI: 1.03 (GM 50.86% / 52.15%) |
| AQI: 0.82 (AQ_t 0.46 / AQ_t-1 0.56) |
| SGI: 0.93 (Revenue 3.62b / 3.90b) |
| TATA: -0.20 (NI -882.0m - CFO 221.0m) / TA 5.65b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of XRAY shares?
Over the past week, the price has changed by +10.34%, over one month by +11.24%, over three months by +26.67% and over the past year by -24.87%.
Is XRAY a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 13
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the XRAY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | -5.3% |
| Analysts Target Price | 13 | -5.3% |
| ValueRay Target Price | 12.7 | -7.9% |
XRAY Fundamental Data Overview February 03, 2026
P/S = 0.6866
P/B = 1.6836
P/EG = 0.7769
Revenue TTM = 3.62b USD
EBIT TTM = -780.0m USD
EBITDA TTM = -432.0m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 378.0m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.12b USD (from netDebt column, last quarter)
Enterprise Value = 4.61b USD (2.49b + Debt 2.48b - CCE 363.0m)
Interest Coverage Ratio = -9.87 (Ebit TTM -780.0m / Interest Expense TTM 79.0m)
EV/FCF = 57.57x (Enterprise Value 4.61b / FCF TTM 80.0m)
FCF Yield = 1.74% (FCF TTM 80.0m / Enterprise Value 4.61b)
FCF Margin = 2.21% (FCF TTM 80.0m / Revenue TTM 3.62b)
Net Margin = -24.34% (Net Income TTM -882.0m / Revenue TTM 3.62b)
Gross Margin = 50.86% ((Revenue TTM 3.62b - Cost of Revenue TTM 1.78b) / Revenue TTM)
Gross Margin QoQ = 48.78% (prev 52.35%)
Tobins Q-Ratio = 0.81 (Enterprise Value 4.61b / Total Assets 5.65b)
Interest Expense / Debt = 0.93% (Interest Expense 23.0m / Debt 2.48b)
Taxrate = 21.0% (US default 21%)
NOPAT = -616.2m (EBIT -780.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.47 (Total Current Assets 2.07b / Total Current Liabilities 1.41b)
Debt / Equity = 1.68 (Debt 2.48b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -4.90 (negative EBITDA) (Net Debt 2.12b / EBITDA -432.0m)
Debt / FCF = 26.46 (Net Debt 2.12b / FCF TTM 80.0m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.37% (Net Income -882.0m / Total Assets 5.65b)
RoE = -47.74% (Net Income TTM -882.0m / Total Stockholder Equity 1.85b)
RoCE = -20.18% (EBIT -780.0m / Capital Employed (Equity 1.85b + L.T.Debt 2.02b))
RoIC = -14.80% (negative operating profit) (NOPAT -616.2m / Invested Capital 4.16b)
WACC = 5.41% (E(2.49b)/V(4.97b) * Re(10.08%) + D(2.48b)/V(4.97b) * Rd(0.93%) * (1-Tc(0.21)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.74%
[DCF Debug] Terminal Value 82.23% ; FCFF base≈194.0m ; Y1≈139.1m ; Y5≈75.7m
Fair Price DCF = 1.28 (EV 2.37b - Net Debt 2.12b = Equity 254.7m / Shares 199.6m; r=5.90% [WACC]; 5y FCF grow -33.29% → 2.90% )
EPS Correlation: -58.50 | EPS CAGR: -24.65% | SUE: -1.08 | # QB: 0
Revenue Correlation: -72.60 | Revenue CAGR: -4.82% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.38 | Chg30d=-0.014 | Revisions Net=-1 | Analysts=11
EPS next Year (2026-12-31): EPS=1.52 | Chg30d=-0.050 | Revisions Net=-1 | Growth EPS=-5.9% | Growth Revenue=+0.7%